NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Trying to determine how VS-6063 received permission for a large phase II blinded study without more early pfs data. They kept showing slides of 12 day tumor shrinkage in phase I study, but nothing additional regarding pfs except they would bring up a Japanese patient that was doing well. Maybe because mesothelioma is such a man made disease, it went to trial faster....dunno. DCVax-L's trial started after multiple phase I/II studies, compassionate use experience, prior tripling of pfs, etc.

The other take away/difference is that DCVax-L suspended enrollment screening temporarily, and at the same time appears to be expanding its Memphis facility into next year, Woodford continued to invest in August, it appears enrollment continued even after new screenings were suspended, and the company made certain nobody confused suspension with trial halt. (Shorts trying to turn "good news into bad news.") Moreover, there is the work of RRR and Senti which seems to indicate clinics thought the new temporary screening/recruitment suspension were for positive reasons. Multiple German clinics pursuing reimbursement for HE. Continued treatment of patients in the trial. NWBO filing documents with regulators and two way communication. This does not at all look like VS-6063.